Search results “Tumor board and national cancer registry”
2 Abstracting
An abstract is a record that contains information about each patient from the time of diagnosis and continuing throughout his or her life. The abstract includes patient data about demographics, diagnostic studies, cancer staging, treatment, and follow-up. When they create and update abstracts, cancer registrars must follow abstracting rules set by their individual state central registries. Hospitals that are accredited through the American College of Surgeons Commission on Cancer (ACoS/CoC) also follow ACoS/CoC abstracting rules and standards. Cancer registries transmit abstract data to their state’s cancer registry and, if the facility is ACoS/CoC-accredited, to the National Cancer Data Base (NCDB).
Views: 2665 NCRA News
National Amyotrophic lateral sclerosis (ALS) Registry -- Impact, Challenges, and Future Directions
Amyotrophic lateral sclerosis (ALS), sometimes called Lou Gehrig’s disease, is a rapidly progressive, fatal neurological disease caused by degeneration of motor neurons in the brain and spinal cord. Researchers don’t know what causes ALS and there is no cure. Approximately 80 percent of persons with ALS die within 2-5 years of diagnosis. Comments on this video are allowed in accordance with our comment policy: http://www.cdc.gov/SocialMedia/Tools/CommentPolicy.html This video can also be viewed at https://www.cdc.gov/video/phgr/2017/GR_04-18-2017.mp4
Cancer and Family History: Using Genomics for Prevention
The risk factors for cancer are many and varied, and inherited genetic mutations play a major role in 5 to 10% of all cancers. When these mutations are identified early, patients are able to work with their healthcare providers to take crucial steps toward care and treatment. Comments on this video are allowed in accordance with our comment policy: http://www.cdc.gov/SocialMedia/Tools/CommentPolicy.html This video can also be viewed at https://www.cdc.gov/video/phgr/2016/GR_04-19-2016-lo-res.mp4
Reprogramming the Immune System to Fight Cancer
Speaker: PD Dr. med. Jens Hasskarl, Hematologist, Oncologist, Global Clinical Leader CTL019 Novartis Pharma AG, Basel (CH) "Pushing the Limits in Novel Medicine ‐ Gene Transfer, Cells, Targeting, Materials" Chair Dr. med. h.c. Beat Löffler, MA, European Foundation for Clinical Nanomedicine, Basel (CH) and Prof. Dr. Lajos P. Balogh, Editor‐in‐Chief, Nanomedicine, Nanotechnology, Biology and Medicine, Elsevier and Member of the Executive Board, American Society for Nanomedicine, Boston (USA)) Day 2 Hall Montreal CLINAM 2015 The European Summit for Clinical Nanomedicine and Targeted Medicine – The Translation to Knowledge Based Medicine Eighth Conference and Exhibition, June 30 2015
Views: 357 TAUVOD
Medical Radiation and cancer risk: assessing the price of progress
Medical Radiation and cancer risk: assessing the price of progress Air date: Friday, January 11, 2013, 12:00:00 PM Category: NIH Director's Seminars Runtime: 01:02:02 Description: NIH Director's Seminar Radiation exposure to the US population from diagnostic imaging has increased 6-fold in the last three decades, primarily due to the rapid increase in CT scans from 1 to 80 million per year. Despite the great medical benefits there are concerns about the potential future cancer risks from CT and other higher dose imaging tests such as nuclear medicine cardiac stress tests. Dr. Berrington's Radiation Epidemiology Branch conducted the first study to directly assess the cancer risks after CT scans in a historical cohort study of 200,000 children in the UK. Dr. Berrington will discuss the first results from this study and also present risk projections for the number of future cancers in the US that may be related to diagnostic imaging in children and adults if use continues at current levels. Recently a number of new screening tests such as lung CT and CT colonography have been proposed for use in the general population, and newer radiotherapy techniques like proton therapy have become more widespread. Dr. Berrington will also describe work that she has conducted that assesses the balance of the potential benefits against the radiation-related cancer risks for these emerging technologies. Permanent link: https://videocast.nih.gov/launch.asp?17744
Views: 396 nihvcast
Vaccine Pioneer Mocked Attempting to Expose Merck - Cancer Causing Virus in Vaccine
VOICE OF DOCTOR MAURICEHILLEMAN Bill Gates And The SV40 Cancer-Causing Virus By David Jenkins 6-22-11 Read at: http://rense.com/general94/bill.htm   The new (GMO-DNA) vaccines contain SV40.   Wikipedia, in an article on DNA vaccination includes this reference to SV40:   "The SV40 promoter was conventionally used until research showed that vectors driven by the Rous Sarcoma Virus (RSV) promoter had much higher expression rates.[2] ... An example of DNA vaccine plasmid is pVAC, it uses SV40 promoter.     The SV40 Cancer Foundation, however, goes into more detail.   "SV40 was the 40th virus found in rhesus monkey kidney cells when these cells were used to make the polio vaccine. This virus contaminated both the Inactivated Polio Vaccine (IPV) created by Dr. Jonas Salk and the Oral or "Live" Polio Vaccine (OPV) created by Dr. Albert Sabin.   "In 1961, SV40 was discovered by Dr. Bernice Eddy of the National Institute of Health, Division of Biologics when she took the material used to grow polio vaccines and injected it into hamsters. Tumors grew in the hamsters. Her discovery was subsequently validated by Drs. Maurice Hilliman and Benjamin Sweet of Merck.     Children being fed sugar cubes with the oral polio vaccine. Circa 1961.   "Upon the discovery that SV40 was an animal carcinogen that had found its way into the polio vaccines, a new federal law was passed in 1961 that required that no vaccines contain this virus. However, this law did not require that SV40 contaminated vaccines be thrown away or that the contaminated seed material (used to make all polio vaccines for the next four decades) be discarded. As a result, known SV40 contaminated vaccines were injected into children up until 1963. In addition, it has been alleged that there have been SV40-contaminated batches of oral polio vaccine administered to some children until the end of the 1990's.   Dr. Robert Bell, once Vice President International Society for Cancer Research at the British Cancer Hospital said:   "The chief, if not the sole, cause of the monstrous increase in cancer has been vaccination."    Hillerman, chief of vaccines at Merck not only validated Bernice Eddy's discovery but he admitted that all Merck's vaccines contain cancer viruses and other viruses and that their Hepatitis vaccine caused the AIDS epidemic in the US.   Dr. Larry Palevsky, a NY board certified pediatrician, agrees as well that vaccines contain viruses and says that most of the viruses in vaccines can not be removed.   The new vaccines are GMO-DNA vaccines.  The material that they wish to inject has been genetically engineered (thus GMO) using parts of viruses, cancers, animal poxes, and combined, and are then shot or inhaled or injected into the body, to be "taken up by the DNA" (thus DNA) . This material is meant to affect the body in the most fundamental way possible, by affecting the very coding of the body (the DNA) which controls functions for the existence of the person.   And doesn't SV40's potential uptake by the child or adult's DNA present a much graver danger than previously?  Could this cancer virus now become part of the body's coding itself?   SV40 was removed by federal law.  So, is against federal law to introduce it into vaccines again?  And is it not an extreme threat to anyone taking the new vaccines, to have it taken up by their DNA?   Bill Gates wants every newborn on earth registered for vaccination, with cell phones to alert parents as well as locate people.     The Redmond, Wash.-based company's cofounder and chairman envisioned collecting biometric information on babies via handsets and transmitting the data to a central health registry, which could be used to remind parents about vaccinations. GPS data from the phone could also help guide medical personnel to remote locations to administer vaccines.   Continue reading at: http://rense.com/general94/bill.htm Other: SV40 CANCER FOUNDATION http://www.sv40foundation.org/CPV-link.html Transcript of audio interview with Dr. Maurice Hilleman http://www.naturalnews.com/033584_Dr_Maurice_Hilleman_SV40.html
Anne LanierAnne P. (Pelizzoni) Lanier, M.D.
As a family practice physician, medical epidemiologist, researcher and administrator, Anne Lanier has worked to improve health among Alaska’s Native people since 1967. Starting as a physician at the Alaska Native Medical Center, she saw too many young Alaska Native people dying of cancer. She asked why and, finding no answers, she determined to seek them. In 1974 Lanier created the Alaska Native Tumor Registry, one of 18 National Cancer Institute’s Surveillance Epidemiology and End Results registries, to determine cancer rates and patterns throughout the U.S. Her data-driven research has led to dramatic declines in incidence and mortality rates in pediatric liver and cervical cancer among Alaska’s Native people. She always published her data so others could review her conclusions. Lanier was the first female director of the Centers for Disease Control and Prevention’s Arctic Investigations Program. She initiated the Alaska Native Epidemiology Center and later created the Alaska Native Health Consortium’s Office of Alaska Native Health Research. Lanier currently is a consultant for the Alaska Native Tribal Health Consortium in Anchorage. In 1982 Lanier became a Fellow of the American Board of Preventative Medicine. In 2011 she received the inaugural Carol Frieden Award for Extraordinary Leadership in Comprehensive Cancer Control from the Centers for Disease Control and Prevention. After graduating from Lawrence University in Appleton, Wis., in 1962, Lanier earned her M.D. degree from Washington University School of Medicine in 1966 and completed a Masters of Public Health degree at the University of Minnesota School of Public Health in 1975. She did an internship at Presbyterian Hospital in Denver, Colo., before taking her first job in Alaska. Lanier has three children and five grandchildren. She is a reader, skier, kayaker, and traveler. She has mentored several generations of health researchers and personally funds a scholarship at the University of Alaska Anchorage for those pursuing master’s degrees in public health.
Colon Cancer Under 50: Latest Update On the Numbers
While we know about the rise in this disease in those under 50, recent studies put an alarming fact into hard focus: you're never too young for colon cancer. Hematology-oncology specialist Dr. Jason Zell discusses this trend, as well as new research showing that the science behind this disease is changing. #TheAntiCancer | http://www.anti-cancer.com Get patient stories, wellness tips, health care news and more on our Live Well blog: http://www.ucirvinehealth.org/blog UC Irvine Health | http://www.ucirvinehealth.org
Views: 167 UCI Health
We Were There - PVC and Angiosarcoma
"We Were There" lecture series' latest lecture video titled "How a Rare Cancer Changed the Workplace and Environment - PVC and Angiosarcoma" Comments on this video are allowed in accordance with our comment policy: http://www.cdc.gov/SocialMedia/Tools/CommentPolicy.html This video can also be viewed at http://www.cdc.gov/video/WWT_PVC/WWT-Rare_Cancer_04-24-2018_LowRes.mp4
Li-Fraumeni Syndrome: Discovery and Future Challenges
In May 2014, NCI’s Division of Cancer Epidemiology and Genetics (DCEG) hosted “Cancer Epidemiology: From Pedigrees to Populations,” a scientific symposium honoring 50 years of visionary leadership by Dr. Joseph F. Fraumeni, Jr., the founding Director of DCEG. In this video, Dr. Stephen Chanock of NCI provides opening remarks. Dr. David Schottenfeld of the University of Michigan moderates a session on the search for cancer susceptibility genes. Dr. Louise Strong of University of Texas MD Anderson Cancer Center speaks about the discovery and future challenges of Li-Fraumeni syndrome research. For more information on this symposium, visit http://dceg.cancer.gov/news-events/Fraumeni-symposium-speakers
Snowy does Vero !
Snowy gets his tail treated thanks to BrainLab at AAPM
Views: 370 lizzieread1968
INSIGHTS ON PBS HAWAII - Should Hawaii Require All Children to Be Vaccinated?
Measles outbreaks linked to unvaccinated children on the mainland have many in Hawaii questioning whether our vaccination requirements are strong enough to prevent an outbreak here. Although several vaccinations are required to attend public schools, parents who believe the shots are dangerous or unnecessary can seek exemptions for religious and medical reasons. But now that the nearly eradicated measles virus has returned, should exemptions for healthy children still be allowed? Malia Mattoch moderates this discussion.
Views: 6409 PBSHawaiiorg
Panel: equity does not mean treating everyone the same
Seven leading cancer experts join facilitator Dr. Norman Swan to address the issue of equity and accessible cancer care in NSW. Dr. Norman Swan chairs a discussion on the issue of equity and how to open access and increase better outcomes for priority populations. The panel of experts explores the theme by discussing programs in Aboriginal communities, issues with health literacy and low socio-economic effects and generational divides. This insightful panel discussion also addresses rural barriers currently affecting indigenous cancer patients, the role of general practitioners, the effects of data to improve outcomes, current projects, mapping patient journeys, quality of safety in Aboriginal and culturally and linguistically diverse communities and the role of Aboriginal health workers. Panel members include: Raj Verma, Director Clinical Program Design and Implementation, Agency for Clinical Innovation (ACI) Eve Propper, person living with cancer (or cancer survivor) Dr. Astrid Perry, Manager Multicultural Health, South Eastern Sydney Local Health District Dea Delaney-Thiele, Regional Co-ordinator, Population Health Unit, Aboriginal Medical Service, Western Sydney A/Prof Mathew George, Medical Oncologist, North West Cancer Centre Prof. Jon Emery, Winthrop Professor of General Practice, University of Western Sydney Prof. David Currow, Chief Cancer Officer and Chief Executive Officer, Cancer Institute NSW
Views: 283 cancerNSW
Why your prostate cancer volumes are declining
https://www.advisory.com/Research/Oncology-Roundtable/Multimedia/Video/2015/Why-your-prostate-cancer-volumes-are-declining Prostate cancer volumes are experiencing a steep decline: according to the Florida Cancer Data System, the number of new cases fell by nearly half between 2011 and 2013. What's powering this dramatic shift, and what trends can cancer programs expect in the future? In our video, we break down data available in The Journal of the American Medical Association and explain what factors are behind the drop in prostate cancer diagnoses, from new screening guidelines to the use of active surveillance. We also talk about how these numbers will change going forward.
Views: 157 Advisory Board
Director's Report (May 2016) - Eric Green
May 16, 2016 - National Advisory Council for Human Genome Research More: https://www.genome.gov/27564922/
TCRC Rapid Fire Session
Cancer Institute NSW Innovations Conference 2017
Views: 38 cancerNSW
Medical Cannabis and  Its Impact on Human Health a Cannabis Documentary
In this myth shattering, information packed documentary, learn from physicians and leading researchers about medicinal cannabis and its demonstrated effects on human health. This game-changing movie presents the most comprehensive synopsis to date of the real science surrounding the world's most controversial plant. Topics include: * What the consensus is from over 1500 scientific and medical trials * What conditions have been proven to benefit from medical marijuana * Its historical use as medicine dating back over 5300 years * Methods of delivery and their different advantages * Government sponsored studies intended to show Marijuana having negative effects that yielded the exact opposite results * Common myths about negative effects of Marijuana and what the research really says about these topics Doctors: Dr. David Bearman Expert Witness Former Director of Haight Ashbury Drug Treatment Program Founder of Isla Vista Medical Clinic Member of Governor Reagan's Inter-Agency Task Force on Drug Abuse Dr. Donald TashkinDr. Donald Tashkin Emeritus Professor of Medicine UCLA Medical Director of UCLA Pulmonary Function Laboratory Dr. Donald AbramsDr. Donald Abrams Director, Integrative Oncology Research Program Integrative Medicine Physician. Professor of Clinical Medicine at UCSF and Chief of Hematology/Oncology at San Francisco General Hospital Dr. Robert SternerDr. Robert Sterner UCSD General Surgeon Graduate of Harvard & UCLA Certified in Oriental and Traditional Chinese Medicine Credits: * James Schmachtenberger (Executive Producer) * Lindsey Ward (Director/Producer) * Troy Brajkovich (Director of Photography) Visit: http://www.MarijuanaMovie.Org Directors YT: MindzEyeFilm Download Link: http://v20.lschache4.c.youtube.com/Medical%20Cannabis%20and%20Its%20Impact%20on%20Human%20Health%20a%20Cannabis%20Documentary.mp4 (you might need to right click and "save as") Captions text link: http://textuploader.com/?p=6&id=BDe7j
The Importance of Clinical Research for Minority and Underserved Communities
Three NCI researchers and grantees discuss how minority participation in clinical research can benefit ethnic and underserved populations. African American, Asian American, and Hispanic populations are featured.
Welcome & Introduction to Fibrous Dysplasia
This is one of fifteen videos recorded by the Fibrous Dysplasia Foundation at the 2014 Patient and Family Conference. It was held at the NYU Langone Medical Center, New York, NY on October 25-26, 2014. Fibrous Dysplasia Foundation website: http://www.fibrousdysplasia.org Speaker Information: Charles W. Harles Charlie Harles was a founder and is now president of the Fibrous Dysplasia Foundation, established to provide information, advocacy, support, and research on FD, Mc-Cune Albright Syndrome and cherubism. Charlie was first diagnosed at age seven or eight and did not meet another person with FD/MAS until he was over 50 years old. Charlie has been participating in several studies and advocating for persons with FD and MAS at NIH. Though Charlie has had to use crutches or a wheelchair since childhood and has had many fractures and surgeries, he pursued a legal career (JD from University of North Carolina) focused on providing job training and employment for persons with disabilities. Dr. Michael Collins Dr. Collins is the Chief of the Skeletal Clinical Studies Unit at National Institutes of Health in Bethesda, Maryland. His research is focused on the study of bone biology and mineral metabolism. One of his primary foci of research is fibrous dysplasia of bone and McCune-Albright syndrome. Dr. Collins is the author of many scholarly articles on FD/MAS and has cared for more than 200 patients with FD/MAS over the last 15 years at the NIH. He has dedicated a large part of his career to advancing the understanding of FD/MAS, improving the quality of life of patients with FD/MAS through better treatments. He has been involved with the FD Foundation since its inception and serves on the Board of Medical Advisors to the Foundation.
Views: 1153 FD Foundation Inc
National Assembly for Wales Plenary 19.06.18
Plenary is the meeting of the whole Assembly which takes place in the Siambr, the Senedd’s debating chamber. Plenary is chaired by the Presiding Officer and is the main forum for Assembly Members to carry out their roles as democratically elected representatives. Plenary takes place twice a week on Tuesdays and Wednesdays and is open to the public, you can also watch it live or on demand here on YouTube or on Senedd.TV.
Views: 41 AssemblyCynulliad
The Lung Cancer Living Room™ - Patient Registry - March 21, 2017 - Half-hour Episode
Join Kyle Brown of Invitae, as he discusses the importance of creating an online patient profile. By registering on lungcancerregistry.org, lung cancer patients can contribute to a growing collection of data that drives important decisions in the medical arena.
InFocus: Lung disease awareness
Lung cancer is the leading cause of cancer deaths in the world, killing more people than breast, colorectal and prostate cancers combined.
Views: 46 WWLP-22News
Genome-wide association studies in Cancer: A Step in the Right Direction: Stephen Chanock
Stephen Chanock M.D. from the National Cancer Institute presents Genome-wide association studies in Cancer: A Step in the Right Direction
Views: 1141 NCIwebinars
NCI Implementation Science Webinar -- Rapid, Responsive, and Relevant Research (R3)
This webinar, hosted by the NCI's Implementation Science Team examines potential ways that we can improve the research enterprise system to design and implement research that is more rapid, responsive, and relevant and features a presentation by Dr. Bill Riley and commentary by Dr. Russ Glasgow, Dr. Amy Abernethy, and Dr. Lynn Etheredge.
Screening for Colorectal Cancer: Optimizing Quality (CME). Primary Care Version Part 1
Part 1 of the Primary Care Version CME includes basic information about colorectal cancer and screening, factors that affect when and how patients should be screened, and detailed screening and surveillance guidelines based on personal and family history. It is the first of three parts of a continuing education activity that provides guidance and tools for clinicians on the optimal ways to implement screening for colorectal cancer to help ensure that patients receive maximum benefit. For more information, visit https://www.cdc.gov/cancer/colorectal/quality/. Comments on this video are allowed in accordance with our comment policy: http://www.cdc.gov/SocialMedia/Tools/CommentPolicy.html This video can also be viewed at https://www.cdc.gov/cancer/videos/colorectal/quality/Primary_Care1/CRC_Screening_Optimizing_Quality_Primary_Care1_lowres.mp4
Transforming NF Research
Children's Tumor Foundation Webinar Transforming NF Research: Children's Tumor Foundation as a Bridge Between Researchers, Clinicians, and Biotech Panelists: John Risner, President, Children's Tumor Foundation Annette Bakker, Chief Scientific Officer, Children's Tumor Foundation Moderator: Simon Vukelj, Director of Communications, Children's Tumor Foundation *** Please note the captioned text was provided in a rough‑draft format by Communication Access Realtime Translation (CART), which is provided in order to facilitate communication accessibility and may not be a totally verbatim record of the proceedings.
Views: 662 childrenstumor
Dr. Paul Turek: "A Guy's Guide to Maintaining Sexual Health" | Talks at Google
Dr. Paul Turek, an international thought leader on men's health issues, will present an overview of sexual health for men at any age. This talk will address the concepts and cures for common sexual issues such as low sex drive, infertility, hormonal disturbances and other conditions that affect reproduction.
Views: 22607 Talks at Google
Pharmacogenomics - Howard McLeod (2016)
May 4, 2016 - Current Topics in Genome Analysis 2016 More: http://www.genome.gov/CTGA2016
Director's Report (May 2012) - Eric Green
National Advisory Council for Human Genome Research National Institutes of Health May 21-22, 2012 More: http://www.genome.gov/27548774
Brain Tumors: Symptoms, Treatment, and Recovery | Steve Adubato | Caucus NJ
While there isn't a cure to diagnosed primary brain tumors, 35,000 individuals are diagnosed each year. A diagnosis like this raises questions for patients and their loved ones about what the future holds -- from available treatment options to appropriate care. This panel touches upon the different stages of treatment, the various operational procedures available and the practices of post-surgery rehabilitation. Guests include: Joseph C. Landolfi, DO, Medical Director, JFK Brain Tumor Center; Allison Hoffman, Patient of Dr. Landolf; Ilana Unger, MS, OTR/L, Senior Occupational Therapist, Kessler Institute for Rehabilitation; Stan Shrodo, Support Group Leader, The Central New Jersey Brain Tumor Support Group & Resource Center 12/29/12 #2420
Views: 921 Steve Adubato
The Lung Cancer Living Room™ - Sacramento: Expert Panel - March 2017 - Half-Hour Episode
Hear from a panel of experts in the field of lung cancer diagnosis, treatment and future advancements. Learn the importance and benefits of individualized or “precision medicine” when being treated for lung cancer. Filmed on March 23, 2017 in Sacramento, CA. Moderator: Dr. Costanzo DiPerna, MD -Dignity Health- Thoracic Surgeon Panel: Dr. Megan Daly, MD- UC Davis- Radiation Oncology Dr. Deepti Behl, MD-Sutter-Medical Oncology Dr. Peter Murphy, MD- Dignity Health- Pulmonology Rachel McConachie-Dignity Health-Nurse Navigator
"Graft-Versus-Host Disease" by Christine Duncan for OPENPediatrics
Please visit: www.openpediatrics.org OPENPediatrics™ is an interactive digital learning platform for healthcare clinicians sponsored by Boston Children's Hospital and in collaboration with the World Federation of Pediatric Intensive and Critical Care Societies. It is designed to promote the exchange of knowledge between healthcare providers around the world caring for critically ill children in all resource settings. The content includes internationally recognized experts teaching the full range of topics on the care of critically ill children. All content is peer-reviewed and open access-and thus at no expense to the user. For further information on how to enroll, please email: openpediatrics@childrens.harvard.edu Please note: OPENPediatrics does not support nor control any related videos in the sidebar, these are placed by Youtube. We apologize for any inconvenience this may cause.
Views: 4704 OPENPediatrics
American Brain Tumor Association 5K LA 2015
RD Photo Services Presents: American Brain Tumor Association 5K LA 2015- Slideshow of the days event at Fairplex, Pomona.
Cancer Epidemiology over the Last Half-Century and Thoughts on the Future
In May 2012, NCI's Division of Cancer Epidemiology and Genetics (DCEG) welcomed David Schottenfeld, M.D. as a Visiting Scholar. Dr. Schottenfeld is the John G. Searle Professor Emeritus of Epidemiology at the University of Michigan School of Public Health and Professor Emeritus of Internal Medicine at the University of Michigan Medical School. He has collaborated with several investigators in DCEG, particularly, Joseph F. Fraumeni, Jr., M.D., Senior Investigator and Advisor to NCI, NIH and Former Division Director of DCEG. Drs. Fraumeni and Schottenfeld each have over fifty years of experience in the field of epidemiology, and they have co-edited the definitive textbook Cancer Epidemiology and Prevention. During this special visit, they participated in a panel discussion, moderated by Robert N. Hoover, M.D., Sc.D., Director of the Epidemiology and Biostatistics Program in DCEG, on "Cancer Epidemiology over the Last Half-Century and Thoughts on the Future". The discussion focused on their personal reflections about their past mentors and colleagues, noteworthy contributions to the field, and how cancer epidemiology has evolved as a discipline. To view highlights from the discussion, visit: http://dceg.cancer.gov/fraumeni-schottenfeld-video
Views: 562 NCIwebinars
AIHI Seminar Series 2017 - Professor David Goldstein
The Translational Cancer Research Network (TCRN) is a Translational Cancer Research Centre based at UNSW and funded by the Cancer Institute NSW. Founded in 2011, the TCRN brings together researchers and clinicians from across its member groups including UNSW Sydney, hospitals within the South East Sydney Local Health District, University Technology Sydney, Border Medical Oncology and the Australian Institute of Health Innovation. The Cancer Institute identified translational research as an area to focus research support to supplement the usual research funding models that focus upon preclinical scientific discovery or clinical trials. The focus of such research is intended to be on mainstream application of novel approaches to care emerging from preclinical or preliminary clinical research or clinical observation leading to novel directions for preclinical research. The goals of the TCRN are to foster a sustainable culture of translational research and develop a sustainable cancer focussed workforce. Examples of the TCRN work in biobanking and bioinformatics and hereditary cancer will be used as examples of potential system change, identification of potential metrics to assess impact in partnership with the AIHI, and our planned future program will be outlined. Professor Goldstein is a conjoint clinical professor at the UNSW Prince of Wales Clinical school. He is the director of the UNSW Cancer Institute NSW Translational Cancer Research Centre – the Translational Cancer Research Network [TCRN] of which the AIHI is a key member. The TCRN belongs to a network of centres established to aggregate translational cancer research in NSW. He has been involved in a variety of clinical research projects ranging from laboratory basic science to novel therapeutics trials to psychosocial aspects of Cancer care. He has been PI of a number of NHMRC and Cancer Australia funded therapeutic trials including both investigator initiated and as Australian PI for multinational studies. He has also been involved with psychosocial and cross cultural/CALD research for many years. His clinical interests are treatment of GI malignancies including pancreas cancer, colorectal cancer, anal carcinoma, hepatobiliary and upper GI malignancy and renal cell carcinoma and lymphoma. He is the adult program leader of the newly formed UNSW Cancer Survivors Centre and is involved with a research program associated with survivorship issues. As part of this activity, he is the Chief Investigator of a Cancer Institute NSW translational program grant of $3,100,000 to study the impact of chemotherapy induced peripheral neuropathy. He also actively participates in three laboratory research programs dealing with stromal biology, pancreas drug resistance and modelling optimal targeted therapies in sarcoma. Professor Goldstein has over 250 co-authored peer reviewed publications and has presented at numerous national and international meetings: USA – ASCO, Japan - Japan Pancreas Society, Gastro week and medical oncology group, New Zealand, S. Korea, Singapore, COSA ASM. Professor Goldstein is a past president of the Clinical Oncology Society of Australia and was a long serving board member of the Australasian Gastrointestinal Trials Group over 11 years and was treasurer for most of that time. He is currently the project leader for the ASCO/HVO cancer program in Hue Vietnam, as well as being a member of the supervisory committee of all HVO cancer projects.
The 2017 Jeffrey M. Trent Lecture in Cancer Research - Katherine A. Janeway
September 6, 2017 Lecture Title: Bringing Genomics to the Pediatric Oncology Clinic: Diagnosis, Treatment Selection and Rational Clinical Trial Design More: https://www.genome.gov/27568937
Building a Cancer Program in Sub-Saharan Africa: The AMPATH-Oncology Model
Cancer has emerged as the leading cause of death in low- and middle-income countries. Many countries, especially in sub-Saharan Africa are ill prepared to handle this evolving crisis in medical care. Building on the successful collaborative partnership centered on HIV-AIDS is the AMPATH-Oncology program (the Academic Model for Providing Access to Healthcare), which is focused on enhancing the research, educational and clinical care infrastructure for western Kenya. This presentation will provide the background and current status of this ongoing experiment in health care delivery. View the other videos in this series www.cancer.gov/globalhealth/events/seminarseries
Views: 457 NCIwebinars
The Lancet Oncology Commission: Future Cancer Research Priorities in the USA — Part 2
The Lancet Oncology Commission: Future Cancer Research Priorities in the USA — Part 2 Top scientists discuss how they recommend expanding and implementing the Blue Ribbon Panel’s road map for cancer research. They’ll discuss a report that will be published by the journal The Lancet Oncology and is co-edited by Elizabeth Jaffee, M.D., deputy director of the Johns Hopkins Kimmel Cancer Center, and Chi Van Dang, M.D., Ph.D., scientific director at Ludwig Cancer Research and professor at The Wistar Institute. Visit Johns Hopkins inHealth at: https://www.hopkinsmedicine.org/inhealth
How Do You Become A Radiation Therapist?
Radiation therapy technician education requirements study. There are mainly certification and associate programs in georgia radiation therapy is the treatment management of cancer by. Become a radiation therapist? . How to become a radiation therapist verywell. How to become a radiation therapist radiology technician. Radiation therapists career, salary and education information radiation therapist schools programs why i chose to become a oncolink cancer careers the college board. How to become a radiation therapist 7 steps (with pictures). How can i become a radiation therapist? Learn. The therapist operates an x ray or ct (computer 16 apr 2015 you need to complete a tertiary education before can become radiation. $83k $107k chances of getting work as a radiation therapist are average, but better in larger cities working with people in various stages of cancer, radiation therapists become a main source of support and comfort for patients and families. Become a radiation therapist? Find detailed explanation of the education and certification needed to become therapist how. Becoming a radiation therapist what is it really like? Youtube. How do you become a radiation therapist healthtimes. Our graduates are the radiation therapist administers to patient. Radiation therapists bureau of labor statisticsbcit radiation therapy full time, bachelor science. Is there any radiation therapists or people studying careers in therapy asmirt. If you are still at school, it is important to take subjects explore the career requirements for radiation therapists. Get the facts about job duties, education, licensure requirements and potential prospective students searching for radiation therapy technician education found following related articles links useful 8 may 2017 learn how to become a therapist, what they do, average salaries, in this overview of careers 2radiation therapists treat cancer other diseases patients by administering go do one there are no certification requirements, but employers often prefer certified therapists, who have passed national examinations that verify their 27 mar 2013 many career options within oncology field person chooses which path make profession can depend therapist is. Radiation therapy university of toronto joint program the. Explore the academic path to this career see if it's right one for you my wife has ba in psychology and she want become radiation therapist. The modality plays a how do i become radiation therapist? This discipline students wanting to pursue career as therapist will have available many online therapy programs, designed help them begin their therapists treat cancer and other diseases in patients by administering treatments with extra responsibilities can earn. As a radiation therapist, you can help treat patients with cancer. Where else can i learn about becoming a radiation therapist? Professional associations certificate examination with the american registry of radiologic technologists (arrt) and b
Views: 85 new sparky
Science for Kids: Arctic Mission
This video shows how researchers from the University of Washington collect data to help understand how melting sea ice in the Arctic is affecting weather patterns around the world.
Views: 543 JISAOvideos
Clinical Trials 101
Clinical trials are research studies that involve people and test new ways to prevent, detect, diagnose, or treat cancer and other diseases. At the conclusion of this webinar, you will be able to demonstrate a basic understanding of the basics of clinical trials, including how they work, protections for participants and factors related to participation.
Views: 4229 NCIwebinars
Braids of Truth Introduction
A short introduction to the 3-part series "Braids of Truth" an exploration of Traditional Ecological Knowledge, Climate Change and Collaboration Challenges.
Views: 962 27KSKC
Sheila K. Riggs Radiation Oncology Center at GBMC
Sheila K. Riggs Radiation Oncology Center The Radiation Oncology Center provides advanced radiation therapy to cancer patients. GBMC offers 3D conformal radiation therapy, intensity modulated radiation therapy (IMRT), imaged- guided radiation therapy (IGRT), transperineal prostate implants, a wide array of brachytherapy treatments, stereotactic radiosurgery, and radioimmunotherapy. Through participation in national clinical trials, the department helps identify and bring the most promising therapies and new cancer treatments to our patients as soon as possible. For example, GBMC was the first community hospital in the area and one of few institutions nationwide to offer the sophisticated Intensity Modulated Radiation Therapy (IMRT) to oncology patients. The Radiation Oncology Center is a statewide model of excellence. Patient care is paramount. All patients are provided with the highest quality of radiotherapeutic care. Board-certified radiation oncologists and a board-certified medical physicist are on staff. Patient satisfaction survey results show that 97% of the patients participating in the survey have had a good to excellent experience. A recent special medical report issue of Baltimore Magazine named each of the radiation oncologists as "Top Doctors". The Top Doctor recognition is a peer-review honor, where fellow physicians name doctors who they would recommend to loved ones. Radiation therapy is multidisciplinary. It requires teamwork from a variety of professionals to provide quality care to cancer patients. Our radiation oncology team consists of radiation oncologists, radiation oncology nurses, radiation therapists, medical dosimetrists, medical physicists, medical assistant, secretaries, receptionists, and volunteers. The radiation oncologist is the patient's physician in the department. He or she is board certified with the American Board of Radiology to treat cancer with radiation. The radiation oncologist prescribes the dose of radiation and manages the patient's treatment and/or side of effects. In addition, the radiation oncologist follows the patient's post treatment. Radiation oncology nurses work closely with the radiation oncologist to manage side effects. This includes educating the patient about side effects and the necessary steps to minimize side effects. The nurses also make recommendations about diet and skin care. Radiation therapists are health care professionals certified in radiation therapy by the American Registry of Radiologic Technology. Radiation therapists deliver the radiation treatment by operating the linear accelerator. Radiation therapists also participate in the simulation process and aid in the education of patients. Medical dosimetrists are responsible for providing treatment plans that meet and adhere to the radiation oncologist prescription. Medical physicists are responsible for providing clinical physics service and quality assurance. Medical assistants work in all aspects of department work, such as clerical, nursing, and radiation therapist duties. Secretaries are responsible for the radiation oncologists' schedules and making sure that the physicians have all necessary records for consultations. The receptionists greet patients daily and schedule follow up appointments.
Registries and Universal Screenings: Opportunities and Challenges in Various Settings
In this presentation during the February 2017 Workshop on Approaches to Blue Ribbon Panel Recommendations: The Case of Lynch Syndrome, Dr. Nancy Baxter, Dr. Noralane Lindor, Dr. Mark Jenkins, Dr. Debra Duquette, Dr. Heather Hampel, Dr. Jessica Ezzell Hunter, and Dr. Karen Lu discuss registries and universal screening, along with questions and comments from the audience. Learn more about this Workshop at https://cancercontrol.cancer.gov/lynch-syndrome-workshop/
Views: 82 NCIwebinars
UW 360 December 2011: Tidal Energy
University of Washington scientists assess the possibilities for electricity generated by tidal currents in Puget Sound, including environmental impacts.
Views: 3144 UWTV
Director's Report (September 2015) - Eric Green
September 21, 2015 - National Advisory Council for Human Genome Research More: http://www.genome.gov/27562458
NINR Big Data Boot Camp Part 3: Big Data Analytics for Healthcare - Dr. Bonnie Westra
The National Institute of Nursing Research (NINR) Big Data in Symptoms Research Boot Camp, part of the NINR Symptom Research Methodologies Series, is a one-week intensive research training course at the National Institutes of Health (NIH) in Bethesda, Maryland. NINR's 2015 Boot Camp provided a foundation in data science focusing on methodologies and strategies for incorporating novel methods into research proposals. Since there was a high demand for the course, the first day of the Big Data Boot Camp was videocast live and is now available in segments on the NINR YouTube channel. To learn more visit www.ninr.nih.gov/bootcamp. Part 3 features Dr. Bonnie Westra of the University of Minnesota discussing Big Data Analytics for Healthcare.
Views: 852 NINRnews
City of Santa Rosa Council Meeting June 5, 2018
City meeting agendas, packets, archives, and live stream are always available at https://santa-rosa.legistar.com
Thomas DeLuca - Managing Soil Carbon in Temperate & Boreal Ecosystems Part 2
Thomas DeLuca is the Professor and Director of the School of Environment and Forest Sciences at the University of Washington. His presentation is about managing soil carbon in temperate and boreal ecosystems. When US forests stopped being harvested in an aggressive and unsustainable manner, carbon became primarily stored instead of released into the environment. There is an increased interest in securing storage of carbon in terrestrial plants and soils because of human induced CO2 loading of the atmosphere. DeLuca argues it is also important to consider the influence carbon has on the physical, chemical and biological properties of the soil, since this strongly influences the biotic potential of a landscape. This presentation was a part of the Alberta Soil Science Workshop, February 2015.
Views: 68 LanduseKN